Kairos Pharma Statistics
Total Valuation
Kairos Pharma has a market cap or net worth of $18.75 million. The enterprise value is $15.67 million.
Market Cap | 18.75M |
Enterprise Value | 15.67M |
Important Dates
The last earnings date was Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Kairos Pharma has 12.84 million shares outstanding. The number of shares has increased by 2.97% in one year.
Current Share Class | 12.84M |
Shares Outstanding | 12.84M |
Shares Change (YoY) | +2.97% |
Shares Change (QoQ) | +3.29% |
Owned by Insiders (%) | 59.24% |
Owned by Institutions (%) | 0.10% |
Float | 4.06M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 5.63 |
P/TBV Ratio | 6.11 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.04.
Current Ratio | 2.84 |
Quick Ratio | 1.92 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -2.63 |
Financial Efficiency
Return on equity (ROE) is -375.74% and return on invested capital (ROIC) is -111.98%.
Return on Equity (ROE) | -375.74% |
Return on Assets (ROA) | -41.71% |
Return on Capital (ROIC) | -111.98% |
Revenue Per Employee | n/a |
Profits Per Employee | -$913,667 |
Employee Count | 3 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 44.96 |
Average Volume (20 Days) | 717,971 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -1.99M |
Pretax Income | -812,000 |
Net Income | -2.74M |
EBITDA | -1.83M |
EBIT | -1.99M |
Earnings Per Share (EPS) | -$0.26 |
Balance Sheet
The company has $3.22 million in cash and $142,000 in debt, giving a net cash position of $3.08 million or $0.24 per share.
Cash & Cash Equivalents | 3.22M |
Total Debt | 142,000 |
Net Cash | 3.08M |
Net Cash Per Share | $0.24 |
Equity (Book Value) | 3.33M |
Book Value Per Share | 0.26 |
Working Capital | 3.07M |
Cash Flow
Operating Cash Flow | -2.09M |
Capital Expenditures | n/a |
Free Cash Flow | -2.09M |
FCF Per Share | -$0.16 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Kairos Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.97% |
Shareholder Yield | -2.97% |
Earnings Yield | -14.62% |
FCF Yield | -11.13% |
Analyst Forecast
The average price target for Kairos Pharma is $9.00, which is 516.44% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $9.00 |
Price Target Difference | 516.44% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |